Fresenius Kabi, a global healthcare company that has been in China for approximately 40 years, ranks among the top 10 non-Chinese pharmaceutical firms in the country, according to President and CEO Pierluigi Antonelli.

Antonelli said China is one of the company's top three global markets, alongside its operations in over 100 countries. He emphasized the enduring appeal of the Chinese market and noted its significant growth potential. He said that healthcare spending in China was around 1.3 trillion euros in 2022 (about $1.4 trillion) and is projected to rise to 2.4 trillion euros (about $2.6 trillion) U.S. by 2030.

Adding that he has visited China three times in the past 16 months, Antonelli said he is impressed by the country's clear development strategy and rapid progress and expressed confidence in Fresenius Kabi's continued presence in China.